Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells

• US 8,435,745 B2
• Filed: 03/19/2010
• Issued: 05/07/2013
• Est. Priority Date: 02/14/2005
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Bilsborough, Janine M., Gross, Jane A.
• Primary Examiner(s): STANFIELD, CHERIE MICHELLE
• Application Number:
  US12/727,912
• Publication Number:
  US 20100266600A1
• Time in Patent Office: 1,145 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• CPC Class Codes: A61K 49/006 Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: G01N 33/505 involving T-cells
• CPC Class Codes: G01N 33/6869 : Interleukin
• CPC Class Codes: G01N 33/6881 : from skin

Abstract

The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.

Claims

1. A method of predicting the therapeutic response to an IL-31 antibody in an individual with atopic dermatitis comprising the steps of:

a. obtaining a skin sample from the individual;

b. obtaining a skin sample from a control;

c. detecting IL-31RA in the skin, wherein the IL-31RA is detected with an anti-IL-31 RA antibody having a concentration of between 665 ng/ml to 1330 ng/ml; and

d. correlating a greater amount of IL-31 RA in the individual versus the control with a therapeutic response to the IL-31 antibody.

2. The method of claim 1, wherein the IL-31 RA is detected by immunohistochemical staining.

3. The method of claim 1, wherein the IL-31RA is detected in epidermal keratinocytes.

4. The method of claim 1, wherein the IL-31RA is detected on perivascular infiltrating cells.

5. The method of claim 4, wherein the perivascular infiltrating cells are detected with an antibody specific for the tissue macrophage marker CD68.